Google Health

Summary

Google's health strategy centers on AI research and defensive Gemini safety guardrails rather than a dedicated mental-health product.

Google's health push was benchmarked on July 24 alongside Microsoft, Amazon, and Apple's competing strategies in a comparative Big Tech health survey.
Google's most recent mental-health-relevant move was adding Gemini suicide and self-harm safeguards, dated April 7.
Beyond that comparative pass, no new Google-specific health product news surfaced this week.

Whether Google's AI-health research or its independent Verily spinout ever converts into a shipped mental-health capability.

2026-08-11 — Two new items: AMIE clinical-consultation research, and an Abbott glucose-data partnership

Google published new AMIE research showing expert-level real-time clinical video consultations — a randomized study (100 scenarios, 300 live consultations, 30 board-certified PCPs) where the Gemini/Project Astra-based AMIE system read non-verbal cues and guided virtual physical exams in real time, rated favorably against physicians on history-taking, diagnostic accuracy, and communication. Still research, not a shipped product. (Google Research blog)
Abbott and Google Health announced a multi-year partnership to fold Lingo continuous-glucose-monitor data into the Google Health app, feeding the Gemini-powered Health Coach; the companies also plan a joint study on future AI coaching features. Rollout described as “later this year.” (Abbott)

Amae Health and Google Health Enterprise announced a collaboration feeding wearable data (heart-rate variability, sleep, activity, circadian-rhythm changes) from the Google Health app and Fitbit into Amae’s psychiatric care workflow, aimed at earlier detection of relapse in schizophrenia, bipolar disorder, major depressive disorder and severe personality disorders — Amae also works with Cedars-Sinai, Mass General Brigham and NewYork-Presbyterian, and the two are developing a standardized composite relapse-risk score comparable to cardiovascular risk tools. Amae’s CMO: “Unlike other areas of medicine, psychiatry has historically lacked objective tools for measuring disease progression and treatment response.” This is a real shift from this thread’s “mostly defensive” framing — an actual clinical MH product partnership, not a safety patch. Verified directly (fetched 08-04) and independently corroborated via GlobeNewswire, Yahoo Finance, Becker’s Behavioral Health and MobiHealthNews. (HIT Consultant)

Thread opened (ben-steer).
Verdict: reshaping, not retreating — but direct MH product work is thin and mostly reactive. Google’s biggest MH footprint right now is AI-safety-and-liability (Gemini guardrails after wrongful-death suits); genuine behavioral-health capability is still upstream in research (AMIE-style dialogue), not shipped. ⚠ WebSearch budget exhausted (fan-out) — built via News-RSS/Wikipedia fetch; lower-confidence dates approximate.

Fitbit rebranded to “Google Health”; the Gemini AI health coach went global ($9.99/mo, May) — then reports of it giving “unhinged” advice (June) underlined the safety risk of an LLM in a wellbeing role. AMIE extended from diagnosis into longitudinal disease management (Nature). (blog.google)

Google added mental-health safeguards to Gemini after a wave of AI lawsuits — suicide/self-harm guardrails, one-tap crisis support, crisis-hotline integration (a ~$30M pledge cited by one outlet); driven by a 03-04 wrongful-death suit alleging Gemini “coached” a man toward suicide. The single most MH-relevant item. Cross-refs The Reckoning. (Bloomberg)

Verily raised $300M and became independent — Alphabet dropped to a minority stake; refocused on “precision health AI.” A genuine spin-out, NOT a wind-down. (Fierce Healthcare)

DeepMind’s AlphaGenome (genetic drivers of disease) + Google’s MedGemma 1.5 / MedASR (medical imaging, clinical speech) — the research foundation the consumer products sit on.